Health Care & Life Sciences » Biotechnology | Elanix Biotechnologies AG

Elanix Biotechnologies AG | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
-
-
6.20
328.10
Cost of Goods Sold (COGS) incl. D&A
-
-
1,247.60
1,254.80
1,416.90
Gross Income
-
-
1,247.60
1,248.60
1,088.70
SG&A Expense
49.20
35.00
1,915.50
1,074.50
3,351.80
EBIT
49.20
35.00
-
2,323.10
4,440.50
Unusual Expense
1.00
20.00
-
-
-
Non Operating Income/Expense
69.70
0.20
12.80
22.40
220.20
Pretax Income
119.60
14.90
3,171.30
2,345.50
4,660.70
Income Tax
-
-
382.70
454.90
830.40
Consolidated Net Income
119.60
14.90
2,788.60
1,890.60
3,830.30
Net Income
119.60
14.90
2,788.60
1,890.60
3,830.30
Net Income After Extraordinaries
119.60
14.90
2,788.60
1,890.60
3,830.30
Net Income Available to Common
119.60
14.90
2,788.60
1,890.60
3,830.30
EPS (Basic)
0.22
0.03
0.51
0.34
0.58
Basic Shares Outstanding
544.80
544.80
5,447.80
5,607.20
6,585.20
EPS (Diluted)
0.22
0.03
0.51
0.34
0.58
Diluted Shares Outstanding
544.80
544.80
5,447.80
5,607.20
6,585.20
EBITDA
17.20
-
1,911.00
1,071.80
3,181.30
Other Operating Expense
-
-
4.60
-
-
Non-Operating Interest Income
0.30
-
-
-
-

About Elanix Biotechnologies

View Profile
Address
Hohenstaufenstrasse 1
Wiesbaden Hessen 65189
Germany
Employees -
Website http://www.elanix-biotechnologies.de
Updated 07/08/2019
Elanix Biotechnologies AG operates as a holding company, which engages in the development and marketing of progenitor cell-based products for acute wound care, as well as dermatological and gynecological applications. It operates through the Regenerative Medicine and Cosmetic Ointments business segments. The Regenerative Medicine segment offers skin dressings made from progenitor skin fibroblasts to provide protection and accelerated healing for burns and reconstructive surgery.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.